Valion Bio Reports Q1 2026 Earnings and Strategic Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 37 minutes ago
0mins
Should l Buy VBIO?
Source: seekingalpha
- Financial Overview: Valion Bio reported a net loss of $6.2 million for Q1 2026, significantly up from a $1.5 million loss a year earlier, reflecting high operating costs associated with business expansion, although the loss per share improved from $2.52 to $2.23.
- R&D Spending Increase: Research and development expenses for the quarter reached $1.9 million, a substantial rise from $0.3 million in Q1 2025, indicating the company's ongoing commitment to accelerating the clinical development of Entolimod.
- Strategic Plans and Risks: Management highlighted future strategic initiatives, including initiating physician-sponsored studies for neutropenia in the second half of 2026, while also addressing financing and listing risks that could impact operational capabilities and market performance.
- Cash Flow Status: As of March 31, 2026, Valion Bio had cash and cash equivalents of $7.2 million, down from $12.6 million at the end of 2025, with $5 million used in operating activities during Q1, indicating pressure on the company's financial management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VBIO
Wall Street analysts forecast VBIO stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 0.968
Low
Averages
High
Current: 0.968
Low
Averages
High
No data
About VBIO
Valion Bio, Inc., formerly Tivic Health Systems, Inc., is a late-stage immunotherapeutics company. The Company offers Entolimod, which is a drug used to treat acute radiation syndrome (ARS). Entolimod is a toll-like receptor 5 (TLR5) agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. Its pipeline also includes Entolimod to treat neutropenia and lymphocyte exhaustion, as well as Entolasta, an immunologically optimized variant of Entolimod for chronic applications. Its subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that is based in San Antonio, Texas. It offers upstream and downstream process development and optimization; analytical testing, assay development, and qualification; quality control and stability testing; microbial and mammalian expression systems; technology transfer and program management services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Valion Bio Reports Q1 2026 Earnings and Strategic Outlook
- Financial Overview: Valion Bio reported a net loss of $6.2 million for Q1 2026, significantly up from a $1.5 million loss a year earlier, reflecting high operating costs associated with business expansion, although the loss per share improved from $2.52 to $2.23.
- R&D Spending Increase: Research and development expenses for the quarter reached $1.9 million, a substantial rise from $0.3 million in Q1 2025, indicating the company's ongoing commitment to accelerating the clinical development of Entolimod.
- Strategic Plans and Risks: Management highlighted future strategic initiatives, including initiating physician-sponsored studies for neutropenia in the second half of 2026, while also addressing financing and listing risks that could impact operational capabilities and market performance.
- Cash Flow Status: As of March 31, 2026, Valion Bio had cash and cash equivalents of $7.2 million, down from $12.6 million at the end of 2025, with $5 million used in operating activities during Q1, indicating pressure on the company's financial management.
See More
Velocity Bioworks Secures Exclusive Agreement with LarmorBio for BioScan-NMR Platform
- Exclusive Agreement: Velocity Bioworks has entered into an exclusive commercial development and licensing agreement with LarmorBio for the BioScan-NMR™ platform, with the first commercial installation targeted for July 2026 in San Antonio, thereby enhancing the company's market position in next-generation NMR diagnostics.
- Strategic Partnership: This agreement establishes a strategic partnership between Velocity Bioworks and LarmorBio, with both parties commercially and operationally aligned to validate, optimize, and scale the deployment of the BioScan-NMR platform, thereby strengthening their competitive edge in the market.
- First-Mover Advantage: By hosting the first commercial installation of the BioScan-NMR platform, Velocity Bioworks gains a first-mover advantage, serving as a demonstration and validation site for LarmorBio's broader commercial pipeline, which enhances its service capabilities in biomanufacturing.
- Technology Integration and Investment: This collaboration not only provides Velocity Bioworks with advanced diagnostic services but also complements LarmorBio's upcoming Series A financing, ensuring the company's continued investment and technological leadership in the biotechnology sector.
See More
Velocity Bioworks Partners with LarmorBio for NMR Diagnostics
- Exclusive Agreement: Velocity Bioworks has entered into an exclusive commercial development and licensing agreement with LarmorBio, targeting the first installation of the BioScan-NMR™ platform in San Antonio by July 2026, positioning the company at the forefront of next-generation NMR diagnostics.
- Strategic Partnership: This agreement establishes a strategic partnership between Velocity Bioworks and LarmorBio, aligning both parties commercially and operationally to jointly validate, optimize, and scale the BioScan-NMR platform, enhancing their competitive edge in the market.
- First-Mover Advantage: By hosting the first commercial installation of the BioScan-NMR platform, Velocity Bioworks gains a first-mover advantage, which is expected to strengthen its position in biomanufacturing and clinical diagnostics services, attracting more customers and investment.
- Integration and Growth: This initiative not only supports Velocity Bioworks' internal drug development pipeline but also provides advanced diagnostic services to third-party CDMO clients, anticipated to lower costs and accelerate production efficiency, driving long-term growth for the company.
See More
Valion Bio to Report Q1 2026 Financial Results on May 14
- Earnings Report Schedule: Valion Bio is set to announce its Q1 2026 financial results after market close on May 14, which is expected to provide critical insights into the company's financial health and business updates, potentially influencing investor confidence.
- Conference Call and Webcast: Management will host a conference call and webcast, with participants able to join by dialing 888-506-0062 or 973-528-0011, access code 118764, ensuring investors receive real-time updates on the company's latest developments.
- Product Development Progress: Valion Bio is developing Entolimod™, which has received Fast Track and Orphan Drug designations from the FDA, aimed at treating Acute Radiation Syndrome and oncology supportive care, showcasing the company's potential in the biotherapeutics sector.
- Enhanced Manufacturing Capabilities: Valion Bio's wholly-owned subsidiary, Velocity Bioworks, offers contract development and manufacturing services, leveraging its capabilities to advance its drug pipeline, which is expected to lower costs and accelerate production timelines, thereby enhancing market competitiveness.
See More
Valion Bio Opens New Facility to Enhance Cancer Treatment Capabilities
- Facility Launch: Valion Bio's Velocity Bioworks facility in San Antonio officially opens, marking the activation of the company's vertically integrated manufacturing strategy, which is expected to enhance production capabilities for Entolimod™, addressing the needs of cancer patients and U.S. warfighters.
- Strategic Recognition: The facility's opening was acknowledged by Senator John Cornyn and San Antonio Mayor Gina Ortiz Jones, highlighting its significance in the bioscience economy and national preparedness, which is anticipated to stimulate regional economic growth.
- Successful Tech Transfer: Velocity Bioworks recently completed a successful tech transfer of the Entolimod manufacturing process with incremental scale-up activities to support GMP manufacturing, which is expected to accelerate the product's market entry and enhance competitive positioning.
- Talent Concentration: The new facility employs approximately 45 scientists and engineers, with San Antonio chosen for its convergence of life sciences talent and strategic logistics infrastructure, which is expected to drive further growth in the biopharmaceutical sector.
See More
Valion Bio Secures NIAID Funding to Advance Entolimod Research
- Study Protocol Approval: Valion Bio's agreement with NIAID, valued at up to $7 million, aims to support the Biologics License Application (BLA) for Entolimod™, marking a significant advancement in the acute radiation syndrome (ARS) field.
- Preclinical Research Initiation: The first study protocol will evaluate Entolimod™'s efficacy in partial-body irradiation gastrointestinal acute radiation syndrome, addressing a gap where no FDA-approved drug currently exists, potentially positioning Entolimod™ as the only drug with dual protective capabilities.
- Funding and Knowledge Support: NIAID not only provides funding but also commits to collaborating with Valion Bio during the FDA submission process, significantly reducing project risk and enhancing the likelihood of success through government-backed support.
- Accelerated Clinical Development: Valion Bio plans to redirect the $7 million originally allocated for Entolimod™ towards the clinical development of its second-generation molecule, Entolasta™, demonstrating the company's strategy of advancing multiple research fronts simultaneously, thereby enhancing the overall potential of its commercial pipeline.
See More
Valion Bio Reports Q1 2026 Earnings and Strategic Outlook
- Financial Overview: Valion Bio reported a net loss of $6.2 million for Q1 2026, significantly up from a $1.5 million loss a year earlier, reflecting high operating costs associated with business expansion, although the loss per share improved from $2.52 to $2.23.
- R&D Spending Increase: Research and development expenses for the quarter reached $1.9 million, a substantial rise from $0.3 million in Q1 2025, indicating the company's ongoing commitment to accelerating the clinical development of Entolimod.
- Strategic Plans and Risks: Management highlighted future strategic initiatives, including initiating physician-sponsored studies for neutropenia in the second half of 2026, while also addressing financing and listing risks that could impact operational capabilities and market performance.
- Cash Flow Status: As of March 31, 2026, Valion Bio had cash and cash equivalents of $7.2 million, down from $12.6 million at the end of 2025, with $5 million used in operating activities during Q1, indicating pressure on the company's financial management.
See More
Velocity Bioworks Secures Exclusive Agreement with LarmorBio for BioScan-NMR Platform
- Exclusive Agreement: Velocity Bioworks has entered into an exclusive commercial development and licensing agreement with LarmorBio for the BioScan-NMR™ platform, with the first commercial installation targeted for July 2026 in San Antonio, thereby enhancing the company's market position in next-generation NMR diagnostics.
- Strategic Partnership: This agreement establishes a strategic partnership between Velocity Bioworks and LarmorBio, with both parties commercially and operationally aligned to validate, optimize, and scale the deployment of the BioScan-NMR platform, thereby strengthening their competitive edge in the market.
- First-Mover Advantage: By hosting the first commercial installation of the BioScan-NMR platform, Velocity Bioworks gains a first-mover advantage, serving as a demonstration and validation site for LarmorBio's broader commercial pipeline, which enhances its service capabilities in biomanufacturing.
- Technology Integration and Investment: This collaboration not only provides Velocity Bioworks with advanced diagnostic services but also complements LarmorBio's upcoming Series A financing, ensuring the company's continued investment and technological leadership in the biotechnology sector.
See More
Velocity Bioworks Partners with LarmorBio for NMR Diagnostics
- Exclusive Agreement: Velocity Bioworks has entered into an exclusive commercial development and licensing agreement with LarmorBio, targeting the first installation of the BioScan-NMR™ platform in San Antonio by July 2026, positioning the company at the forefront of next-generation NMR diagnostics.
- Strategic Partnership: This agreement establishes a strategic partnership between Velocity Bioworks and LarmorBio, aligning both parties commercially and operationally to jointly validate, optimize, and scale the BioScan-NMR platform, enhancing their competitive edge in the market.
- First-Mover Advantage: By hosting the first commercial installation of the BioScan-NMR platform, Velocity Bioworks gains a first-mover advantage, which is expected to strengthen its position in biomanufacturing and clinical diagnostics services, attracting more customers and investment.
- Integration and Growth: This initiative not only supports Velocity Bioworks' internal drug development pipeline but also provides advanced diagnostic services to third-party CDMO clients, anticipated to lower costs and accelerate production efficiency, driving long-term growth for the company.
See More
Valion Bio to Report Q1 2026 Financial Results on May 14
- Earnings Report Schedule: Valion Bio is set to announce its Q1 2026 financial results after market close on May 14, which is expected to provide critical insights into the company's financial health and business updates, potentially influencing investor confidence.
- Conference Call and Webcast: Management will host a conference call and webcast, with participants able to join by dialing 888-506-0062 or 973-528-0011, access code 118764, ensuring investors receive real-time updates on the company's latest developments.
- Product Development Progress: Valion Bio is developing Entolimod™, which has received Fast Track and Orphan Drug designations from the FDA, aimed at treating Acute Radiation Syndrome and oncology supportive care, showcasing the company's potential in the biotherapeutics sector.
- Enhanced Manufacturing Capabilities: Valion Bio's wholly-owned subsidiary, Velocity Bioworks, offers contract development and manufacturing services, leveraging its capabilities to advance its drug pipeline, which is expected to lower costs and accelerate production timelines, thereby enhancing market competitiveness.
See More
Valion Bio Opens New Facility to Enhance Cancer Treatment Capabilities
- Facility Launch: Valion Bio's Velocity Bioworks facility in San Antonio officially opens, marking the activation of the company's vertically integrated manufacturing strategy, which is expected to enhance production capabilities for Entolimod™, addressing the needs of cancer patients and U.S. warfighters.
- Strategic Recognition: The facility's opening was acknowledged by Senator John Cornyn and San Antonio Mayor Gina Ortiz Jones, highlighting its significance in the bioscience economy and national preparedness, which is anticipated to stimulate regional economic growth.
- Successful Tech Transfer: Velocity Bioworks recently completed a successful tech transfer of the Entolimod manufacturing process with incremental scale-up activities to support GMP manufacturing, which is expected to accelerate the product's market entry and enhance competitive positioning.
- Talent Concentration: The new facility employs approximately 45 scientists and engineers, with San Antonio chosen for its convergence of life sciences talent and strategic logistics infrastructure, which is expected to drive further growth in the biopharmaceutical sector.
See More
Valion Bio Secures NIAID Funding to Advance Entolimod Research
- Study Protocol Approval: Valion Bio's agreement with NIAID, valued at up to $7 million, aims to support the Biologics License Application (BLA) for Entolimod™, marking a significant advancement in the acute radiation syndrome (ARS) field.
- Preclinical Research Initiation: The first study protocol will evaluate Entolimod™'s efficacy in partial-body irradiation gastrointestinal acute radiation syndrome, addressing a gap where no FDA-approved drug currently exists, potentially positioning Entolimod™ as the only drug with dual protective capabilities.
- Funding and Knowledge Support: NIAID not only provides funding but also commits to collaborating with Valion Bio during the FDA submission process, significantly reducing project risk and enhancing the likelihood of success through government-backed support.
- Accelerated Clinical Development: Valion Bio plans to redirect the $7 million originally allocated for Entolimod™ towards the clinical development of its second-generation molecule, Entolasta™, demonstrating the company's strategy of advancing multiple research fronts simultaneously, thereby enhancing the overall potential of its commercial pipeline.
See More
